Inhalable dry powder formulations comprising angiogenesis inhibitors

Abstract

Abstract The present invention relates to inhalable dry powder formulations comprising one or more antibodies or one or more angiogenesis inhibiting active pharmaceutical ingredients, methods of manufacture of such compositions, e.g. via spray drying, as well as their local administration to the lung for use in the treatment, prevention and / or delay of progression of asthma, COPD, lung infections, cystic fibrosis, or lung cancer. Abstract 20 26 20 55 20 10 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 5 2 0 1 0 J u l 2 0 2 6

Images